Erratum: Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter (Gene Therapy (2004) vol. 11 (645-648) 10.1038/sj.gt.3302089);Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter

Gene Therapy

Volumn 11, Issue 7, 2004, Pages 645-648

  Zhu, Z B ^a   Makhija, S K ^b   Lu, B ^a   Wang, M ^c   Kaliberova, L ^a   Liu, B ^a   Rivera, A A ^a   Nettelbeck, D M ^a   Mahasreshti, P J ^a   Leath III, C A ^b   Yamaoto, M ^a   Alvarez, R D ^b   Curiel, D T ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Adenoviral vector; CXCR4; Transcriptional targeting; Tumor specific promoter

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE RECEPTOR CXCR4; LUCIFERASE;

ADENOVIRUS; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GENETICS; CELL CYCLE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HOST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TISSUE SPECIFICITY; TRANSGENE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY; VIRUS RECOMBINANT;

ADENOVIRIDAE; CUCUMBER MOSAIC VIRUS;

EID: 11144356412     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302731     Document Type: Erratum

References (20)

1. Brand K et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther 1997; 4: 9-16.
2. van der Eb MM et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Therapy 1998; 5: 451-458.
3. Haisma HJ et al. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther 2000; 7: 901-904.
4. Heideman DA et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 2001; 8: 342-351.
5. Krasnykh V et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
6. Yamamoto M et al. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001; 3: 385-394.
7. Adachi Y et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001; 61: 7882-7888.
8. Nettelbeck DM, Jerome V, Muller R. Gene therapy: Designer promoters for tumour targeting. Trends Genet 2000; 16: 174-181.
9. Rollins BJ. Chemokines. Blood 1997; 90: 909-928.
10. Wegner SA et al. Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem 1998; 273: 4754-4760.
11. Muller A et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
12. Moore MA. The role of chemoattraction in cancer metastases. Bioessays 2001; 23: 674-676.
13. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002; 118: 915-922.
14. Murakami T et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002; 62: 7328-7334.
15. Taichman RS et al. Use of the stromal cell-derived factor-1/ CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-1837.
16. Haviv YS et al. Targeting renal cancer via the CXCR4 promoter (submitted).
17. Alvarez RD et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2: 524-530.
18. Alvarez RD et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial. Clin Cancer Res 2000; 6: 3081-3087.
19. Nettelbeck DM et al. Cox2 promoter for tumor-specific targeting of adenoviral vector to melanoma. Melanoma Res 2003; 13: 287-292.
20. He TC et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.